Chemistry:Brigimadlin
From HandWiki
| |
| Names | |
|---|---|
| IUPAC name
(3S,10'S,11'S,14'S)-6-chloro-11'-(3-chloro-2-fluorophenyl)-13'-(cyclopropylmethyl)-6'-methyl-2-oxospiro[1H-indole-3,12'-8,9,13-triazatetracyclo[7.6.0.02,7.010,14]pentadeca-1,3,5,7-tetraene]-5'-carboxylic acid
| |
| Identifiers | |
3D model (JSmol)
|
|
| EC Number |
|
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C31H25Cl2FN4O3 | |
| Molar mass | 591.46 g·mol−1 |
| Hazards | |
| GHS pictograms |  
|
| GHS Signal word | Danger |
| H300, H360Df, H372, H413 | |
| P203Script error: No such module "Preview warning".Category:GHS errors, P260, P264, P270, P273, P280, P301+316Script error: No such module "Preview warning".Category:GHS errors, P318Script error: No such module "Preview warning".Category:GHS errors, P319Script error: No such module "Preview warning".Category:GHS errors, P321, P330, P405, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Brigimadlin (BI-907828) is a small molecule MDM2-TP53 inhibitor developed for liposarcoma.[2][3][4][5][6]
References
- ↑ "Brigimadlin" (in en). https://pubchem.ncbi.nlm.nih.gov/compound/129264140#section=Safety-and-Hazards.
- ↑ Rinnenthal, Joerg; Rudolph, Dorothea; Blake, Sophia; Gollner, Andreas; Wernitznig, Andreas; Weyer-Czernilofsky, Ulrike; Haslinger, Christian; Garin-Chesa, Pilar et al. (1 July 2018). "Abstract 4865: BI 907828: A highly potent MDM2 inhibitor with low human dose estimation, designed for high-dose intermittent schedules in the clinic". Cancer Research 78 (13_Supplement): 4865. doi:10.1158/1538-7445.AM2018-4865.
- ↑ Rudolph, Dorothea; Reschke, Markus; Blake, Sophia; Rinnenthal, Jörg; Wernitznig, Andreas; Weyer-Czernilofsky, Ulrike; Gollner, Andreas; Haslinger, Christian et al. (1 July 2018). "Abstract 4866: BI 907828: A novel, potent MDM2 inhibitor that induces antitumor immunologic memory and acts synergistically with an anti-PD-1 antibody in syngeneic mouse models of cancer". Cancer Research 78 (13_Supplement): 4866. doi:10.1158/1538-7445.AM2018-4866.
- ↑ Cornillie, J.; Wozniak, A.; Li, H.; Gebreyohannes, Y. K.; Wellens, J.; Hompes, D.; Debiec-Rychter, M.; Sciot, R. et al. (April 2020). "Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification". Clinical and Translational Oncology 22 (4): 546–554. doi:10.1007/s12094-019-02158-z. PMID 31201607.
- ↑ Schöffski, Patrick; Lahmar, Mehdi; Lucarelli, Anthony; Maki, Robert G (March 2023). "Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS". Future Oncology 19 (9): 621–629. doi:10.2217/fon-2022-1291. PMID 36987836.
- ↑ Schoeffski, P.; Lorusso, P.; Yamamoto, N.; Lugowska, I.; Moreno Garcia, V.; Lauer, U.; Hu, C.; Jayadeva, G. et al. (October 2023). "673P A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours". Annals of Oncology 34: S472–S473. doi:10.1016/j.annonc.2023.09.1859.
 |  |
